More light for Clinuvel
Tuesday, 23 September, 2008
Clinuvel Pharmaceuticals (ASX: CUV) has begun phase II trials of its photoprotective drug afamelanotide (CUV1657) in patients undergoing photodynamic therapy (PDT).
The trial is being conducted in a Parisian hospital and will extend to multiple health-care centres in France.
The first four of an anticipated 30 patients have been dosed, and results are expected within 12 months.
PDT is used to eradicate pre-malignant lesions of the oesophagus and as a palliative therapy in bile duct cancer. It involves administration of porfimer sodium, a photosensitiser, and a targeted light source.
One side effect is phototoxicity, with patients unable to tolerate UV light. Clinuvel anticipates that afamelanotide may offer a photoprotective effect.
Clinuvel is currently in Phase III trials of CUV1657 in erythropoietic protoporphyria (EPP), or abnormal sun sensitivity.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
